WO2010036856A3 - Compatible display vector systems - Google Patents

Compatible display vector systems Download PDF

Info

Publication number
WO2010036856A3
WO2010036856A3 PCT/US2009/058316 US2009058316W WO2010036856A3 WO 2010036856 A3 WO2010036856 A3 WO 2010036856A3 US 2009058316 W US2009058316 W US 2009058316W WO 2010036856 A3 WO2010036856 A3 WO 2010036856A3
Authority
WO
WIPO (PCT)
Prior art keywords
vector systems
display vector
compatible display
pools
antigen binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/058316
Other languages
French (fr)
Other versions
WO2010036856A2 (en
Inventor
Simon Evan Hufton
William James Finlay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Priority to EP09741511A priority Critical patent/EP2364359A2/en
Priority to CA2736904A priority patent/CA2736904A1/en
Priority to JP2011529242A priority patent/JP2012503982A/en
Publication of WO2010036856A2 publication Critical patent/WO2010036856A2/en
Publication of WO2010036856A3 publication Critical patent/WO2010036856A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1041—Ribosome/Polysome display, e.g. SPERT, ARM
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

The present invention provides a polynucleotide vector system used during polypeptide display that can be used to facilitate transfer of pools of polynucleotides encoding antigen binding proteins of interest. The present invention also provides methods that allow seamless conversion of pools of polynucleotides encoding antigen binding proteins using a restriction enzyme digestion and ligation strategy.
PCT/US2009/058316 2008-09-26 2009-09-25 Compatible display vector systems Ceased WO2010036856A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP09741511A EP2364359A2 (en) 2008-09-26 2009-09-25 Compatible display vector systems
CA2736904A CA2736904A1 (en) 2008-09-26 2009-09-25 Compatible display vector systems
JP2011529242A JP2012503982A (en) 2008-09-26 2009-09-25 Compatible display vector system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10043208P 2008-09-26 2008-09-26
US61/100,432 2008-09-26

Publications (2)

Publication Number Publication Date
WO2010036856A2 WO2010036856A2 (en) 2010-04-01
WO2010036856A3 true WO2010036856A3 (en) 2010-07-22

Family

ID=41606692

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/058316 Ceased WO2010036856A2 (en) 2008-09-26 2009-09-25 Compatible display vector systems

Country Status (5)

Country Link
US (2) US8313942B2 (en)
EP (1) EP2364359A2 (en)
JP (1) JP2012503982A (en)
CA (1) CA2736904A1 (en)
WO (1) WO2010036856A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2325311A1 (en) * 2009-11-18 2011-05-25 Pierre Fabre Medicament Novel phage display vector
NZ604510A (en) 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
US20150111773A1 (en) * 2012-06-08 2015-04-23 John Chaput Rapid Affinity Measurement of Peptide Ligands and Reagents Therefor
EP3049558B1 (en) 2013-09-27 2019-07-10 The Board of Trustees of the University of Illionis Method and kit for generating high affinity binding agents
ES2763526T3 (en) * 2014-07-03 2020-05-29 Hoffmann La Roche Polypeptide expression systems

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007109749A2 (en) * 2006-03-21 2007-09-27 Wyeth Methods for preventing and treating amyloidogenic diseases

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
AU638762B2 (en) * 1989-10-05 1993-07-08 Optein Inc Cell-free synthesis and isolation of novel genes and polypeptides
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (en) 1990-07-10 2000-04-17 Cambridge Antibody Tech Process for producing specific binding pair elements
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
ATE414768T1 (en) 1991-04-10 2008-12-15 Scripps Research Inst LIBRARIES OF HETERODIMER RECEPTORS USING PHAGEMIDS
DE4122599C2 (en) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid for screening antibodies
CA2402452A1 (en) * 2000-03-31 2001-10-11 Cambridge Antibody Technology Limited Improvements to ribosome display
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20040058445A1 (en) 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US7244592B2 (en) 2002-03-07 2007-07-17 Dyax Corp. Ligand screening and discovery
KR100607949B1 (en) 2002-09-11 2006-08-03 삼성전자주식회사 Multimedia data recording device, reproducing device and information storage medium using hierarchical information structure
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007109749A2 (en) * 2006-03-21 2007-09-27 Wyeth Methods for preventing and treating amyloidogenic diseases

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
FINLAY W J ET AL: "Affinity Maturation of a Humanized Rat Antibody for Anti-RAGE Therapy: Comprehensive Mutagenesis Reveals a High Level of Mutational Plasticity Both Inside and Outside the Complementarity-Determining Regions", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 388, no. 3, 8 May 2009 (2009-05-08), pages 541 - 558, XP026046499, ISSN: 0022-2836, [retrieved on 20090313] *
GROVES M ET AL: "Affinity maturation of phage display antibody populations using ribosome display", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 313, no. 1-2, 30 June 2006 (2006-06-30), pages 129 - 139, XP025158150, ISSN: 0022-1759, [retrieved on 20060630] *
GROVES MARIA A T ET AL: "Applications of ribosome display to antibody drug discovery", EXPERT OPINION ON BIOLOGICAL THERAPY, INFORMA HEALTHCARE, UK, vol. 5, no. 1, 1 January 2005 (2005-01-01), pages 125 - 135, XP009129349, ISSN: 1744-7682 *
HANES AND A PLÜCKTHUN J: "In vitro selection and evolution of functional proteins by using ribosome display", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCE, vol. 94, 1 May 1997 (1997-05-01), USA, pages 4937 - 4942, XP002079690 *
HE ET AL: "Antibody-ribosome-mRNA (ARM) complexes as efficient selection particles for in vitro display and evolution of antibody combining sites", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, no. 24, 15 December 1997 (1997-12-15), pages 5132 - 5134, XP002079231, ISSN: 0305-1048 *
HOOGENBOOM H R ET AL: "Antibody phage display technology and its applications", IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 4, no. 1, 1 June 1998 (1998-06-01), pages 1 - 20, XP004127382, ISSN: 1380-2933 *
WADA AKIRA ET AL: "Ribosome Display Selection of a Metal-Binding Motif From an Artificial Peptide Library", BIOTECHNOLOGY AND BIOENGINEERING, vol. 101, no. 5, December 2008 (2008-12-01), pages 1102 - 1107, XP002567493, ISSN: 0006-3592 *
ZELENETZ A D ET AL: "Directional cloning of cDNA using a selectable SfiI cassette", GENE, ELSEVIER, AMSTERDAM, NL, vol. 89, no. 1, 30 April 1990 (1990-04-30), pages 123 - 127, XP023545530, ISSN: 0378-1119, [retrieved on 19900430] *

Also Published As

Publication number Publication date
EP2364359A2 (en) 2011-09-14
US20130217597A1 (en) 2013-08-22
JP2012503982A (en) 2012-02-16
CA2736904A1 (en) 2010-04-01
WO2010036856A2 (en) 2010-04-01
US8313942B2 (en) 2012-11-20
US9523092B2 (en) 2016-12-20
US20100120634A1 (en) 2010-05-13

Similar Documents

Publication Publication Date Title
WO2010036860A3 (en) Compatible display vector systems
WO2008071447A8 (en) Amino acid sequences that modulate the interaction between cells of the immune system
WO2010107752A3 (en) Alpha-4-beta-7 heterodimer specific antagonist antibody
JOP20190017A1 (en) Human cgrp receptor binding antibodies
WO2010088517A8 (en) Methods and systems for purifying transferring and/or manipulating nucleic acids
CL2013000074A1 (en) Binding protein with the ability to bind a pair of antigens; nucleic acid encoding it; vector; host cell; Method of production; pharmaceutical composition that includes it; conjugate comprising said binding protein; and its uses
WO2010036856A3 (en) Compatible display vector systems
ZA201200724B (en) Specific sorbent for binding proteins and peptides, and separation method using the same
HK1216894A1 (en) Multivalent binding protein compositions
CL2013001210A1 (en) Multivalent binding protein that binds either tnf and pge2 or vegf and dll4; conjugate that comprises it; nucleic acid encoding it; vector; host cell; Method of production; pharmaceutical composition that includes it; and its uses
WO2011100566A3 (en) Methods for identifying and isolating cells expressing a polypeptide
TN2012000167A1 (en) Human il-23 antigen binding proteins
WO2011146891A3 (en) High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins
WO2013040142A3 (en) Bioinformatic processes for determination of peptide binding
IL223989B (en) Albumin binding polypeptide, fusion protein or conjugate comprising said polypeptide, polynucleotide encoding said albumin binding polypeptide and various aspects related thereto
IL210485A (en) Isolated antibody or a functional protein, process for its preparation, pharmaceutical composition comprising the same and isolated nucleic acid encoding said antibody or functional protein
WO2009004822A1 (en) ANTI-Muc17 ANTIBODY
WO2008005880A3 (en) Antibodies for norovirus
WO2011061625A3 (en) Compositions for increasing polypeptide stability and activity, and related methods
WO2010136483A3 (en) Antigen-binding proteins
WO2012134416A3 (en) Peptide ligands
WO2011055897A3 (en) Fusion protein binding specifically to constant region of antibody, preparation thereof and method for isolating antibody using the same
WO2008136345A1 (en) Polypeptide capable of improving tolerance to iron deficiency in plant, and use thereof
WO2008152422A3 (en) Binding proteins specific for insulin-like growth factors and uses thereof-909
WO2010127180A3 (en) Dc-stamp antibodies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09741511

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2736904

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2011529242

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009741511

Country of ref document: EP